Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corp (NQ: GERN )

3.620 +0.020 (+0.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,673,005
Open 3.650
Bid (Size) 3.520 (2)
Ask (Size) 3.650 (3)
Prev. Close 3.600
Today's Range 3.510 - 3.650
52wk Range 1.180 - 3.840
Shares Outstanding 508,766,846
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Market Mixes It Up With A Broad Rally
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
From Geron Corporation
Via Business Wire

Performance

YTD
+50.83%
+50.83%
1 Month
+31.16%
+31.16%
3 Month
+27.92%
+27.92%
6 Month
+58.08%
+58.08%
1 Year
+174.24%
+174.24%

More News

Read More
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
Via FinancialNewsMedia
Exposures Product Safety
Geron (GERN) Q1 2023 Earnings Call Transcript
Via The Motley Fool
Recap: Geron Q1 Earnings
Via Benzinga
A Preview Of Geron's Earnings
Via Benzinga
Looking Into Geron's Return On Capital Employed
Via Benzinga
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Booz Allen Hamilton, Workday, Marvell Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
The Latest Analyst Ratings for Geron
Via Benzinga
Geron (GERN) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
From Geron Corporation
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
From Geron Corporation
Via Business Wire
Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights
From Geron Corporation
Via Business Wire
Geron to Announce First Quarter 2023 Financial Results on May 11, 2023
From Geron Corporation
Via Business Wire
Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Why Shares of Geron Are Up 30% This Week
Via The Motley Fool
Geron to Present at Upcoming Investor Conferences in April
From Geron Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
Via Benzinga
7 Biotech Stocks Sitting in the Sweet Spot
Via InvestorPlace
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones
From Geron Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.